^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BZ019

    i
    Other names: BZ019, CD19-targeted Chimeric Antigen Receptor T Cells
    Associations

    News

    Trials
    Company:
    Shanghai Cell Therapy Group
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    almost2years
    Study of Efficacy of BZ019 in Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, Shanghai Mengchao Cancer Hospital
    New P2 trial
    |
    CD19 (CD19 Molecule) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    CD20 negative
    |
    cyclophosphamide • BZ019
    4years
    Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital | Recruiting --> Active, not recruiting | N=30 --> 12 | Trial primary completion date: Dec 2019 --> Jul 2020
    Clinical • Enrollment closed • Enrollment change • Trial primary completion date • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    BZ019
    over4years
    Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=21, Recruiting, Shanghai Cell Therapy Group Co.,Ltd
    Clinical • New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    BZ019